Morgan is a fourth year PhD candidate and NSF graduate research fellow in the interdisciplinary Health Sciences and Technology (HST) program at Harvard and MIT. As a member of the Mitragotri Lab at Harvard SEAS, her interests span the fields of drug delivery and cell therapy with ultimate applications in immuno-oncology. Her research focuses on (i) the development of drug delivery technologies to locally manipulate cell therapies and (ii) the use of bioinspired materials to tune the kinetics of cancer vaccines.

Outside of the lab, she is passionate about engaging with the biotech community in Cambridge to create forums for discussion and innovation. She serves as co-president of the MIT Biotech Group and is a co-founder and leader of the Area Two Bio Fund, an investment club for publicly traded biotech companies.

Morgan received her BS in Bioengineering from the University of Maryland. In her free time, she enjoys doing gymnastics, hiking, pageantry, and finding the best matcha lattes in Boston.

‍

HEALTHCARE ADVANCEMENT YOU HOPE TO SEE IN YOUR LIFETIME

"One and done" therapies for chronic, multifactorial diseases like heart disease

‍

MOST INFLUENTIAL CONTENT READ LAST YEAR

Various non-fiction books and articles about gerotherapeutics - drugs with the potential to extend healthspan and lifespan by mitigating age-related disease

‍

RECENT INNOVATION OR DISCOVERY

Base and prime editing, which have greatly expanded the space of genetic diseases potentially addressable using CRISPR